We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ophthotech has signed two deals to bulk up its drug and gene therapy pipeline, following the demise of its lead wet age-related macular degeneration (AMD) candidate last year.